Rallybio Corp (RLYB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RLYB currently has 5.69M outstanding shares. with significant dilution risk as 16M authorized shares could dilute existing holders by 281.1%. The company has minimally diluted shareholders by 5.56% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 5.7M shares outstanding |
5.7M | 16M |
| Mar 16, 2026 |
10-K filing | 5.6M shares outstanding |
5.6M | 16M |
| Nov 06, 2025 |
10-Q filing | 45.1M shares outstanding |
45M | 16M |
| Aug 07, 2025 |
10-Q filing | 44.8M shares outstanding |
45M | 16M |
| Jul 08, 2025 |
8-K filing: Rallybio Corporation entered into a Membership Interest Purchase Agreement with Recursion Pharmaceuticals, Inc., Exscientia Ventures I, Inc., and Rallybio IPB, LLC, pursuant to which Buyer purchased 50% of the membership interests of RE Ventures I, LLC from Seller in exchange for cash and the issuance of shares of Class A Common Stock of Recursion. ($7.5M proceeds) |
45M | 16M |
| May 08, 2025 |
10-Q filing | 44.8M shares outstanding |
45M | 16M |
| Mar 13, 2025 |
10-K filing | 43.5M shares outstanding |
44M | 16M |
| Nov 07, 2024 |
10-Q filing | 44.6M shares outstanding |
45M | 16M |
| Aug 08, 2024 |
10-Q filing | 44.1M shares outstanding |
44M | 16M |
| May 10, 2024 |
S-3 filing: This S-3 filing relates to the potential resale of up to 3,636,363 shares of common stock by a selling stockholder. |
41M | 16M |
| May 09, 2024 |
10-Q filing | 40.8M shares outstanding |
41M | 12M |
| Apr 10, 2024 |
8-K filing: Rallybio Corporation sold 3,636,363 shares of common stock to Johnson & Johnson Innovation - JJDC, Inc. for approximately $6.6 million in gross proceeds on April 10, 2024. ($6.6M proceeds) |
40M | 12M |
| Mar 12, 2024 |
10-K filing | 40.4M shares outstanding |
40M | 12M |
| Nov 09, 2023 |
10-Q filing | 40.5M shares outstanding |
41M | 12M |
| Aug 08, 2023 |
10-Q filing | 40.4M shares outstanding |
40M | 12M |
| May 09, 2023 |
10-Q filing | 40.2M shares outstanding |
40M | 12M |
| May 09, 2023 |
S-3 filing: This is an S-3 filing for the resale of up to 12,351,600 shares of common stock by selling stockholders. |
38M | 12M |
| Mar 06, 2023 |
10-K filing | 38.1M shares outstanding |
38M | 0 |
| Nov 07, 2022 |
10-Q filing | 30.8M shares outstanding |
31M | 0 |
| Aug 08, 2022 |
10-Q filing | 30.6M shares outstanding |
31M | 0 |
| Aug 08, 2022 |
S-3 filing: Rallybio Corporation files an S-3 form to offer and sell common stock, preferred stock, warrants, or units, with a total proposed amount of $300,000,000, subject to completion. |
32M | 0 |
| May 10, 2022 |
10-Q filing | 32.1M shares outstanding |
32M | 0 |
| Mar 15, 2022 |
10-K filing | 32.1M shares outstanding |
32M | 0 |
| Nov 10, 2021 |
10-Q filing | 32.1M shares outstanding |
32M | 0 |
| Sep 09, 2021 |
10-Q filing | 32.1M shares outstanding |
32M | 0 |
| Jul 22, 2021 |
S-1/A filing: This is an S-1/A filing for a common stock offering, including firm shares and optional shares, underwritten by Jefferies, Cowen and Evercore. |
N/A | 0 |
| Jul 02, 2021 |
S-1 filing: The company is offering shares of common stock in an initial public offering. |
N/A | 0 |